Clinical Trial Update: Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating autologous TriMix-DC vaccine plus ipilimumab in previously treated unresectable stage III/IV malignant melanoma; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• TriMix-DC
• ipilimumab (ipilimumab)

Snippet

Sponsor: Bart Neyns | Conditions: Malignant Melanoma Stage III, Malignant Melanoma Stage IV | Phase 2 | Status: COMPLETED